At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 44 enrolled
Drug / intervention
Ritonavir +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Dose-Rising Study of AMD11070 in HIV-Seronegative Men to Assess the Safety and Pharmacokinetics After Single or Multiple Doses
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Jul 8, 2003·Updated Nov 1, 2021
In Brief
A Phase 1 clinical trial evaluating Ritonavir and AMD070 for HIV Infections. Completed, enrolled 44 participants across 2 sites.
Detailed Summary
Most currently approved anti-HIV drugs work by stopping the replication of HIV after it has entered cells. AMD070 (also known as AMD11070) is designed to block HIV from entering cells and may be effective in treating patients who have developed resistance to or are unable to take other anti-HIV drugs. This study will evaluate the safety of different doses of AMD070 along with AMD070 boosted with ritonavir (RTV) in HIV uninfected men.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Timeline
Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2003
Study CompletionOct 2006
TodayJul 2026
First PostedJul 8, 2003
Study CompletionOct 1, 2006
TodayJul 2, 2026
Posted 23.0 years ago
Interventions
Ritonavirdrug
AMD070drug